Since AChEIs, (which induce cholinergic upregulation and activation of α7 nAChRs), are already in clinical use for several neurological indications, such as myasthenia gravis and AD, these agents can also be used for immonomodulation of other neurodegenerative diseases involving neuroinflammation. Here, CHRNA7 is linked to myasthenia gravis.